Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease

Jupiter Neurosciences Begins Phase 2a Enrollment for JOTROL™ in Parkinson's

Jupiter Neurosciences has initiated patient enrollment for its Phase 2a RESET clinical trial (NCT07592767) of JOTROL™ for Parkinson’s Disease. This investigational oral candidate aims to address the significant unmet need for disease-modifying therapies in PD, a market valued at $5.65 billion globally in 2024, affecting 1.1 million people in the U.S. with an annual economic burden of $82.2 billion. JOTROL™ is being evaluated for its potential to target underlying biological drivers of neurodegeneration.

• The multi-center, randomized, double-blind, placebo-controlled Phase 2a RESET study will enroll 30 patients, randomized 1:1:1 to two doses of JOTROL™ or placebo, for a duration of 12 weeks. Primary endpoints include safety, tolerability, and pharmacokinetics in plasma and CSF, while secondary endpoints will assess ATP blood levels and inflammatory biomarkers.
• JOTROL™ demonstrated statistically significant neuroprotective effects, including improved rotarod performance and grip strength, in a well-established Parkinson’s Disease model. Earlier Phase 1 studies in healthy volunteers showed approximately 9-fold higher overall plasma bioavailability compared to conventional resveratrol and measurable CSF drug levels, supporting its central nervous system exposure.
• Parkinson’s Disease represents a substantial unmet medical need, with no disease-modifying therapies currently approved despite affecting over 1.1 million U.S. patients and carrying an estimated annual U.S. economic burden of $82.2 billion. JOTROL™ is positioned as a potentially differentiated therapeutic candidate due to its enhanced CNS exposure and mechanistic profile targeting oxidative stress, mitochondrial dysfunction, and chronic neuroinflammation.

Why Disease-Modifying Therapies are Crucial for Parkinson's

Current Parkinson's disease treatments face fundamental limitations that underscore the urgent need for disease-modifying therapies. Existing approaches primarily manage symptoms rather than addressing underlying neurodegeneration, while standard medications carry significant long-term complications that worsen as the disease progresses.

• Symptom management versus neuroprotection: Current treatments focus on relieving symptoms rather than preventing dopaminergic neuronal damage, with conventional pharmacological approaches showing limited long-term efficacy and no ability to halt disease progression

• Levodopa-related motor complications: The gold standard levodopa therapy is associated with significant motor complications during chronic use, including wearing-off phenomena and dyskinesia, with advanced PD marked by motor fluctuations that progressively lose responsiveness to optimized oral therapy

• Limited efficacy of advanced therapies: Infusion therapies face constraints from adverse effects including infusion-site reactions, risk of hallucinations, invasive procedures, and potential device-related complications, with utilization rates remaining markedly lower than estimated eligible patient populations due to persistent systemic barriers

• Cognitive intervention inconsistencies: Cognitive interventions have yielded mixed results, demonstrating benefits only in specific cognitive domains rather than providing comprehensive cognitive protection

• Safety profile concerns: Certain interventions carry substantial adverse event rates, with apomorphine showing 93% adverse events compared to 57% in placebo groups, highlighting tolerability challenges

• Treatment-resistant patient subsets: Specific patient populations, particularly those with gait impairment, represent ongoing therapeutic challenges, with current evidence not supporting spinal cord stimulation for PD-related gait disorders despite investigation

• Need for personalized approaches: Disease progression necessitates increasingly personalized treatment strategies and fine-tuning according to individual patient needs, moving beyond one-size-fits-all therapeutic paradigms

Understanding Parkinson's Drivers: JOTROL™'s Mechanistic Approach

Parkinson's disease pathogenesis involves complex genetic, molecular, and cellular mechanisms that disrupt normal neuronal function and homeostasis. Genetic factors play a crucial role, with key causative and risk genes encoding protein kinases (PINK1, LRRK2, GAK) and proteins involved in phosphorylation signaling pathways (SNCA, DJ-1). Through transcriptome-wide association studies, 159 PD-associated genes have been identified, with 29 highly credible genes including CTX1B, SCNA, and ARSA. These genes primarily function in tissue synthesis, regulation of neuron projection development, vesicle organization and transportation, and lysosomal processes. Notably, inherited autosomal recessive PD occurs due to mutations in six genes, including PTEN-induced putative kinase1 (PINK1), while genes such as SNCA, LRRK2, GBA, ATP13A2, VPS35, and FBXO7 are implicated in autophagy dysfunction.

At the molecular level, several critical signaling pathways drive PD pathogenesis. PINK1, LRRK2, and other PD-associated gene products are linked to mitogen-activated protein (MAP) and protein kinase B (AKT) kinase signaling pathways. Downstream effectors including C-Jun N-terminal kinase (JNK), extracellular signal-regulated kinases (ERK), and p38 are particularly important, with JNK and p38 playing integral roles in neuronal death. The ERK signaling pathway specifically contributes to l-DOPA-induced dyskinesia development. Central to PD pathology is α-synuclein aggregation and abnormal accumulation in Lewy bodies, which disrupts various cellular processes and contributes to prion-like protein transmission between neurons.

Multiple cellular mechanisms converge to drive neurodegeneration in PD. Mitochondrial dysfunction represents a core pathological feature, with complex I inhibition and impaired mitophagy contributing to dopaminergic neuron vulnerability. Autophagy impairment results in defective protein clearance, leading to accumulation of misfolded proteins and cellular stress. Oxidative stress, calcium homeostasis disruption, and endoplasmic reticulum stress further compromise neuronal survival. Neuroinflammation, characterized by microglial activation and pro-inflammatory cytokine release, occurs early in disease progression and exacerbates nigro-striatal degeneration. The selective vulnerability of dopaminergic neurons in the substantia nigra relates to their high metabolic demands and particular reliance on intracellular calcium for spontaneous activity, making them especially susceptible to these convergent pathological processes.

Jupiter's JOTROL™: Charting a Course for Parkinson's Disease Modification

The journey to find a truly disease-modifying therapy for Parkinson's Disease (PD) has been long and arduous, marked by numerous scientific hurdles and clinical trial setbacks. Current treatments largely focus on managing the debilitating motor and non-motor symptoms, leaving patients and clinicians yearning for an intervention that can slow or stop the relentless progression of neurodegeneration. It is against this backdrop that Jupiter Neurosciences' initiation of its Phase 2a RESET trial for JOTROL™ takes on significant importance.

JOTROL™ aims to address the fundamental biological drivers of PD, a bold and ambitious goal in a disease affecting over a million people in the U.S. alone and carrying an immense economic burden. The global market for PD therapies underscores the substantial commercial opportunity for a successful disease-modifying agent. However, the path forward is fraught with challenges. The complexity of PD's pathophysiology has historically led to a high failure rate for investigational disease-modifying therapies. Even for symptomatic interventions, such as cognitive rehabilitation programs designed to improve executive functioning, demonstrating robust and broad clinical effects on primary endpoints can be difficult, highlighting the high bar for any PD therapy.

As an early-stage Phase 2a trial, the results for JOTROL™ will be closely watched, but they represent only the initial steps in a lengthy development process. While an oral, disease-modifying therapy would offer significant advantages in patient convenience and adherence, the scientific rigor required to prove such a claim is immense. Jupiter Neurosciences is embarking on a high-risk, high-reward endeavor that, if successful, could fundamentally transform the treatment landscape for Parkinson's Disease, offering genuine hope where currently only symptomatic relief exists.